Pharma must improve existing methods to boost solubility as “quantum leap” unlikely

By Nick Taylor

- Last updated on GMT

To boost solubility pharma must develop, refine and improve existing methods as a “quantum leap” in formulation is unlikely, Pharmaterials' CEO said.

Interest in boosting bioavailability has risen as compounds coming through development pipelines have become less soluble. However, improvements to formulation are expected to be gradual.

I don’t think I have seen a dramatically new approach to this. We will develop them, refine, improve, but perhaps not [make] a quantum leap​”, Graham Buckton, CEO of Pharmaterials, a subsidiary of Pii, and professor at the London School of Pharmacy, told in-PharmaTechnologist.

Pharma companies are likely to be receptive to improved techniques. Buckton gave the example of amorphous formulations which were around for decades before being used frequently by industry.

It’s become acceptable out of necessity I imagine​”, Buckton said.

Related news

Show more

Related products

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers